Table 2.
The number and percentage of patients followed for a minimum of 12 months tested for CyR (FISH, BM, or both) or MR (including IS and non-IS). Includes assessments performed after index TKI start date, between 30 days and 3, 6 and 12 months, respectively.
| Monitoring patterns | ||||||
|---|---|---|---|---|---|---|
| During first 3 months of first-line TKI therapy | During first 6 months of first-line TKI therapy | During first 12 months of first-line TKI therapy | ||||
| Italy (n=266) | Europe (n=216) | Italy (n=266) | Europe (n=216) | Italy (n=266) | Europe (n=216) | |
| CyR monitoring Patterns | ||||||
| Done, date present, n (%) | 67 (25.2) | 35 (16.2) | 172 (64.7) | 81 (37.5) | 213 (80.1) | 114 (52.8) |
| Done/recorded with results available* | 64 (95.5) | 29 (82.9) | 160 (93.0) | 72 (88.9) | 202 (94.8) | 101 (88.6) |
| Done/recorded with no results available | 3 (4.5) | 6 (17.1) | 12 (7.0) | 9 (11.1) | 11 (5.2) | 13 (11.4) |
| Not done/recorded, n (%) | 199 (74.8) | 181 (83.8) | 94 (35.3) | 135 (62.5) | 53 (19.9) | 102 (47.2) |
| MR monitoring patterns | ||||||
| Done, date present, n (%) | 89 (33.5) | 73 (33.8) | 216 (81.2) | 185 (85.6) | 263 (98.9) | 206 (95.4) |
| Done/recorded with results on IS, n (%) | 81 (91.0) | 53 (72.6) | 197 (91.2) | 134 (72.4) | 247 (93.9) | 156 (75.7) |
| Done/recorded with results not on IS†, n (%) | 4 (4.5) | 20 (27.4) | 8 (3.7) | 49 (26.5) | 10 (3.8) | 48 (23.3) |
| Done/not recorded, n (%) | 4 (4.5) | 0 (0.0) | 11 (5.1) | 2 (1.1) | 6 (2.3) | 2 (1.0) |
| Not done/recorded, n (%) | 177 (66.5) | 143 (66.2) | 50 (18.8) | 31 (14.4) | 3 (1.1) | 10 (4.6) |
*
The denominator is the total number of patients with a CyR test done with date present.
†
The proportion of MR tests not on the IS includes ‘no’ and ‘unknown’.
BM: bone marrow; CyR: cytogenetic response; FISH: fluorescence in situ hybridization; IS: international scale; MR: molecular response; TKI: tyrosine kinase inhibitor.